• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

    2/14/24 3:30:53 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TGTX alert in real time by email
    SC 13G/A 1 p24-0324sc13ga.htm TG THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    TG Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    88322Q108

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    þ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 88322Q10813G/A Page 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Darwin Global Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Jersey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,046,598 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,046,598 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,046,598 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.7%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 88322Q10813G/A Page 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Dr. Abhishek Trehan

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,046,598 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,046,598 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,046,598 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.7%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 88322Q10813G/A Page 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Darwin Global Master Fund, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,870,511 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,870,511 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,870,511 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.6%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 88322Q10813G/A Page 5 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER
       
      TG Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
      3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560.

     

    Item 2(a). NAME OF PERSON FILING
       
     

    This statement is filed by:

     

    (i) Darwin Global Management, Ltd., a limited company incorporated under the laws of Jersey (“Darwin Global”). The shares of Common Stock (as defined in Item 2(d) below) to which this filing relates are held directly by (a) Master Fund (as defined below), to which Darwin Global serves as investment manager and (b) a sub-account (the “Managed Account”) to which Darwin Global serves as sub-advisor;

     

    (ii) Dr. Abhishek Trehan (“Dr. Trehan”), the Chief Investment Officer and the controlling person of Darwin Global, with respect to the shares of Common Stock held by each of Master Fund and the Managed Account; and

     

    (iii) Darwin Global Master Fund Ltd. (“Master Fund”), a Cayman Islands exempted company, with respect to the shares of Common Stock held by it.

     

    The foregoing persons are hereinafter sometimes each referred to a “Reporting Person” and collectively referred to as the “Reporting Persons.”

     

    The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the business office of each of the Reporting Persons is Whiteley Chambers, Don Street, St. Helier, Jersey JE2 4TR.

     

    Item 2(c). CITIZENSHIP
       
      Darwin Global is a Jersey limited company. Dr. Trehan is a British citizen. Master Fund is a Cayman Islands exempted company.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    CUSIP No. 88322Q10813G/A Page 6 of 8 Pages

     

     

    Item 2(e). CUSIP NUMBER
       
      88322Q108

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) o

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:_________________________________________

     

    Item 4. OWNERSHIP
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.

     

    The percentage set forth in Row 11 of this Schedule 13G is calculated based upon 151,410,073 shares of Common Stock outstanding as of November 1, 2023, as reported in the Issuer’s Quarterly Report for the quarterly period ended September 30, 2023 on Form 10-K filed with the Securities and Exchange Commission on November 6, 2023.

     

    CUSIP No. 88322Q10813G/A Page 7 of 8 Pages

     

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION

     

      Each Reporting Person hereby makes the following certification:
       
      By signing below, each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 88322Q10813G/A Page 8 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 14, 2024

     

    DARWIN GLOBAL MANAGEMENT, LTD.  
       
    /s/ John Legge  
    Name: John Legge  

    Title: Director and Chief Financial Officer

     

     
        /s/ Dr. Abhishek Trehan  
    DR. ABHISHEK TREHAN  

     

     

     
    DARWIN GLOBAL Master fund, LTD.  

     

    By: DARWIN GLOBAL MANAGEMENT, LTD, its investment manager

     
       
    /s/ John Legge  
    Name: John Legge  
    Title: Director and Chief Financial Officer  

     

     

    Get the next $TGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TGTX

    DatePrice TargetRatingAnalyst
    10/29/2024$50.00Buy
    TD Cowen
    8/2/2023$16.00 → $12.00Sell → Neutral
    Goldman
    6/26/2023$55.00 → $40.00Buy
    Jefferies
    5/20/2022$5.00Underperform
    BofA Securities
    2/23/2022$49.00 → $35.00Buy
    B. Riley Securities
    1/28/2022$70.00 → $68.00Buy
    HC Wainwright & Co.
    1/24/2022$75.00 → $70.00Buy
    HC Wainwright & Co.
    12/1/2021$55.00 → $36.00Outperform
    Evercore ISI Group
    More analyst ratings

    $TGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

      First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET    NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly

      5/5/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

      NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au

      4/30/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We were pleased to share three presentations yesterday which we believe demonstrate our continued commitment to improving the patient experience and understanding the long term and real-world profile of BRIUMVI." Mr. Weiss continued, "The results of the retrospective ENAMOR surv

      4/8/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Financials

    Live finance-specific insights

    See more
    • TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

      First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET    NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly

      5/5/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

      NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au

      4/30/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,

      3/3/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      11/14/24 7:45:34 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      2/14/24 3:30:53 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      1/25/24 11:29:01 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by TG Therapeutics Inc.

      10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)

      5/9/25 4:31:06 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

      5/5/25 7:31:59 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by TG Therapeutics Inc.

      DEFA14A - TG THERAPEUTICS, INC. (0001001316) (Filer)

      4/30/25 4:18:47 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

      10/31/24 4:38:40 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

      12/28/22 12:54:09 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for UKONIQ

      Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

      2/9/21 12:05:59 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hume Daniel gifted 62,459 shares, decreasing direct ownership by 26% to 178,030 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      3/18/25 5:01:41 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Charney Laurence N gifted 6,000 shares, decreasing direct ownership by 3% to 201,479 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      3/11/25 5:00:42 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Weiss Michael S was granted 750,000 shares, increasing direct ownership by 6% to 13,824,929 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      1/30/25 5:17:24 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on TG Therapeutics with a new price target

      TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00

      10/29/24 6:30:43 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics upgraded by Goldman with a new price target

      Goldman upgraded TG Therapeutics from Sell to Neutral and set a new price target of $12.00 from $16.00 previously

      8/2/23 8:51:11 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on TG Therapeutics with a new price target

      Jefferies resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $40.00 from $55.00 previously

      6/26/23 9:08:22 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care